Navigation Links
Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
Date:4/7/2013

l development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers. 

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the therapeutic potential of NKTR-214 and the value and potential of our technology and drug candidates in our research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
2. Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry
3. Life Extension Foundation® study finds Cognitex® with NeuroProtection Complex may provide a positive impact on cognitive performance
4. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Scioderm Announces Positive Phase II Data of Topical SD-101 on Wound Closure and Reduction of Lesions and Blisters in Children with Epidermolysis Bullosa (EB)
9. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
10. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
11. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 /CNW/ -   ... after Health Canada tests confirmed it contains two undeclared ... and phenylpropylmethylamine). The distributor, Empire Health Distribution of ... from retail stores across Canada . ... for weight loss and increased energy. ...
(Date:12/24/2014)... Mexico , Dec. 24, 2014  Novastem, ... of its first patient in its study for ... the American Stroke Association, ischemic strokes account for ... to enroll qualified patients in the study, entitled ... Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal ...
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
(Date:12/25/2014)... 2014 Parker & Sons, Inc. an ... and affordable quality regarding heating, cooling and plumbing services ... 2014 by the “Queen of Clean” for impressive contractor ... impressive reputation over the years for providing outstanding quality ... of contractor services for both homeowners and businesses. Linda ...
(Date:12/24/2014)... 25, 2014 AlignLife of Wauwatosa ... afford certain items. During the holiday season, AlignLife looks forward ... 70 toys," says Dr. Sara Mahalko-Leonhardt, owner of AlignLife. "It ... joy, knowing that we are able to give kids toys ... not been for the generosity of our patients." , The ...
(Date:12/24/2014)... Over 700 toys, that’s what AlignLife clinics ... smiling little faces this holiday that might not have ... donations was given to the various charities as well ... through the year. Some of the charities chosen for ... Shrine's Children's Hospitals, Toys for Tots and Crisis Nurseries, ...
(Date:12/24/2014)... Epigenetics finds applications in a large number of fields ... biology, and research for metabolic and genetic disorders. It ... used techniques for the discovery and development of cancer ... rapidly growing worldwide. In 2012, there were 14.1 million ... million people living with cancer (within five years of ...
(Date:12/24/2014)... 2014 Connie Casad, MD, a well-known ... advocate with 30 years of practice experience in Dallas, ... health benefits of dietary detoxification. The second study is ... excellent results from test patients who just completed a ... her interest in conducting the study, Dr. Casad said, ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3
... support product development and clinical evaluation activities, ... Cantimer, Inc., a privately,held company developing and ... in life science, biodefense, environmental,testing, point-of-care diagnostics ... has been awarded a $996,000 contract by ...
... ... WHO: Valley Forge Medical Center & ... ... Valley Forge Medical Center and,Hospital is the first facility on the East Coast to obtain ...
... BeaconEquity.com announces the,availability of TraderNotes on stocks that are ... the daily trading notes for free by visiting:, http://www.BeaconEquity.com/m ... Board: TPIM),RXi Pharmaceuticals Corp. (Nasdaq: RXII ), Vion ... CUR ), Amgen Inc. (Nasdaq: AMGN ),Gilead Sciences ...
... CHICAGO, June 2 Treating pancreatic cancer with a ... is safe and may be beneficial for patients, according ... presented at the 44th annual meeting of the American ... a preliminary study, physicians from the Pancreatic Cancer Center ...
... girls , , MONDAY, June 2 (HealthDay News) -- Children who ... risk of developing autism, new research shows. , The risk ... the study, which was published in the June issue of ... the U.S. Centers for Disease Control and Prevention, helps tease ...
... 2008 Results from an analysis assessing the differences ... employees suffering from multiple sclerosis (MS) being treated with ... by Biogen Idec as poster presentations at the Consortium ... Colorado, May 28-May 31, 2008. The results revealed that ...
Cached Medicine News:Health News:Cantimer, Inc. Awarded $996,000 Contract from U.S. Government to Develop Portable, Real-Time and Non-Invasive Hydration Measurement and Monitoring System for Use by Firefighters 2Health News:Valley Forge Medical Center and Hospital to Become the First Addiction-Free Pain Management Center of Excellence on the East Coast; Will Host Three Day Professional Training Seminar. 2Health News:Valley Forge Medical Center and Hospital to Become the First Addiction-Free Pain Management Center of Excellence on the East Coast; Will Host Three Day Professional Training Seminar. 3Health News:BeaconEquity.com Issues TraderNotes on Biotechnology Stocks: TPIM, RXII, VION, CUR, AMGN, GILD, BIIB, GENR 2Health News:BeaconEquity.com Issues TraderNotes on Biotechnology Stocks: TPIM, RXII, VION, CUR, AMGN, GILD, BIIB, GENR 3Health News:New treatment combination safe for pancreatic cancer patients 2Health News:Being Born Small, Early Raises Autism Risk 2Health News:Being Born Small, Early Raises Autism Risk 3Health News:New data show patients using avonex reported less sick leave and short-term disability costs 2
... are problem enough for your patients. Now you ... functional treatment for foot and ankle fractures and ... A combination of prefabricated brace and open foam ... higher standards of safety. The storm can be ...
... Walker Pediatric Boot is the ... boot that offers superior comfort ... two sizes are offered thus ... will fit left or right, ...
... Bledsoe Mid-Calf Boot is a shorter ... boot designed for second degree ankle ... incision protection. The Bledsoe EZ Set ... of motion from 20 degrees of ...
... The Bledsoe Conformer Diabetic Boot features ... cocoon attached to a unique auto-molding innersole ... mid-sole insert in an aluminum shelled walking ... is designed to evenly distribute body weight ...
Medicine Products: